This HTML5 document contains 147 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1182/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35586880
rdf:type
wikibase:Item
schema:description
מאמר מדעי scienca artikolo 2014年论文 teaduslik artikkel bài báo khoa học articol științific scientific article published on 20 March 2014 2014年论文 2014年論文 tieteellinen artikkeli artigo científico article scientifique наукова стаття, опублікована в березні 2014 სამეცნიერო სტატია artykuł naukowy artikull shkencor videnskabelig artikel научная статья artikel ilmiah บทความทางวิทยาศาสตร์ vedecký článok naučni članak artículu científicu espublizáu en 2014 2014年論文 գիտական հոդված vetenskaplig artikel мақолаи илмӣ scientific article published on 20 March 2014 ২০ মার্চ ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2014年论文 vitskapeleg artikkel wetenschappelijk artikel επιστημονικό άρθρο artigo científico 2014年论文 2014年論文 articolo scientifico artikulong pang-agham vědecký článek 2014 nî lūn-bûn wissenschaftlicher Artikel 2014年论文 2014년 논문 مقالة علمية نشرت في 20 مارس 2014 scientific article published on 20 March 2014 2014年论文 vitenskapelig artikkel 2014年論文 научни чланак artigo científico tudományos cikk научна статия 2014年論文 мақолаи илмӣ artículo científico publicado en 2014 mokslinis straipsnis article científic 2014年の論文 bilimsel makale научни чланак article scientific
p:P577
wds:Q35586880-EECC4284-B338-458B-8182-B5A3D85E8B7A
wdt:P577
2014-03-20T00:00:00Z
p:P407
wds:Q35586880-B2AE9A0A-E2F1-41EA-B249-7CBE1E01F75C
wdt:P407
wd:Q1860
p:P2860
wds:Q35586880-70FB8681-DA83-4B39-A399-D13CE4DBB280 wds:Q35586880-786026E2-C672-4C9F-A64E-8230B9FD5AEF wds:Q35586880-7AAF244F-7BB7-4AE6-ADDA-961756BA63E0 wds:Q35586880-7F61F191-AC5F-4A16-9D83-368040517ADC wds:Q35586880-5D2FADAA-8287-4ABD-917B-046777FEB6AB wds:Q35586880-61C7CE1A-D0A6-4D44-B275-50A064B837CC wds:Q35586880-889FA87B-CAA9-4C51-BBAB-DDB5E1CF52C0 wds:Q35586880-9D5157AF-6898-4D44-B992-783675DDAAA4 wds:Q35586880-A004829C-C3F4-49F4-A48E-198A9C4414A4 wds:Q35586880-CBCDD3BB-E5F3-407C-846E-D4ECFF308F13 wds:Q35586880-E358ADA9-2D64-4EEE-AA70-809F3D83F17D wds:Q35586880-0AA43627-ADC7-4F5D-B19A-9F11CD9A8B2F wds:Q35586880-123F726A-3550-48F4-A852-9A3FCA5041EA wds:Q35586880-29BFF2DE-5075-4C72-9E35-D8689A2490E6 wds:Q35586880-31DDDDE0-D289-4132-BC1C-E58C7CD98E7C wds:Q35586880-3B5FC500-2805-4398-B973-AF4A70C14621
wdt:P2860
wd:Q42926170 wd:Q45059029 wd:Q33401346 wd:Q43609761 wd:Q33399309 wd:Q80501536 wd:Q34192806 wd:Q33393701 wd:Q58033666 wd:Q36360736 wd:Q47582438 wd:Q36822162 wd:Q34589970 wd:Q37122302 wd:Q34594231 wd:Q28301671
p:P2093
wds:Q35586880-0EE47590-C8EF-43FF-A868-5F422CED62C2 wds:Q35586880-0C045CC5-E823-4387-8F60-D21E7050236B wds:Q35586880-E47C5FA3-2619-4139-9E0F-8B92A7F12F5F wds:Q35586880-8D97F16B-1FC1-4558-81E9-CE2D7E2E580F
wdt:P2093
Yasuhiro Oki Dana A Kennedy Eric D Jacobsen Jeff P Sharman
rdfs:label
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
skos:prefLabel
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
schema:name
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
p:P50
wds:Q35586880-0278CBF8-0A50-4627-B9C7-8961F32DA245 wds:Q35586880-E5DE2643-AD02-407E-B882-40B633076C72 wds:Q35586880-3DB54796-5F21-4AFF-A6EA-8FB357A53543 wds:Q35586880-42CE4D8A-4B4B-4203-A45D-305112F5A178 wds:Q35586880-7B743271-4C78-4D2D-A822-50995E9EAC7B
wdt:P50
wd:Q85620133 wd:Q85651732 wd:Q102148850 wd:Q60545128 wd:Q104437536
p:P1476
wds:Q35586880-0C2766DA-487C-48DB-96DC-E66C0B8E406C
wdt:P1476
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
p:P304
wds:Q35586880-60524D42-9B43-4C22-9FC2-36355525D378
wdt:P304
3095-3100
p:P31
wds:Q35586880-5B3D4389-A678-4A37-9F4E-9428EE9A3139
wdt:P31
wd:Q13442814
p:P698
wds:Q35586880-C1539160-DA3C-4B43-ABF3-7CF25D56120C
wdtn:P698
n11:24652992
wdt:P698
24652992
p:P1433
wds:Q35586880-682A8AAD-3769-4C22-8FB4-CEC4EA2E1451
wdt:P1433
wd:Q885070
p:P433
wds:Q35586880-74D9E235-5045-469D-A5EC-66A9F153389A
p:P478
wds:Q35586880-7D95074D-0B0E-4CFC-8C71-5DE6A9EE8150
wdt:P433
20
wdt:P478
123
p:P1104
wds:Q35586880-3C0CFA48-D554-4448-8C90-BE10BE9CD430
wdt:P1104
6
p:P356
wds:Q35586880-E4B70320-D6BB-4F5D-BF7E-7B10728585DC
wdtn:P356
n8:BLOOD-2013-12-542142
wdt:P356
10.1182/BLOOD-2013-12-542142
p:P932
wds:Q35586880-777E38BC-418A-40BA-BAC3-A3BAD3DF7638
wdt:P932
4425442